- Home
- SMBK vs TBPH Comparison
SMBK vs TBPH Comparison
Compare SMBK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBK
- TBPH
- Stock Information
- Founded
- SMBK N/A
- TBPH 2013
- Country
- SMBK United States
- TBPH United States
- Employees
- SMBK N/A
- TBPH N/A
- Industry
- SMBK Major Banks
- TBPH Biotechnology: Pharmaceutical Preparations
- Sector
- SMBK Finance
- TBPH Health Care
- Exchange
- SMBK Nasdaq
- TBPH Nasdaq
- Market Cap
- SMBK 602.3M
- TBPH 699.0M
- IPO Year
- SMBK N/A
- TBPH N/A
- Fundamental
- Price
- SMBK $36.83
- TBPH $14.05
- Analyst Decision
- SMBK Buy
- TBPH Strong Buy
- Analyst Count
- SMBK 4
- TBPH 4
- Target Price
- SMBK $37.25
- TBPH $23.00
- AVG Volume (30 Days)
- SMBK 40.8K
- TBPH 516.3K
- Earning Date
- SMBK 10-20-2025
- TBPH 11-11-2025
- Dividend Yield
- SMBK 0.87%
- TBPH N/A
- EPS Growth
- SMBK 62.51
- TBPH N/A
- EPS
- SMBK 2.47
- TBPH 0.26
- Revenue
- SMBK $178,959,000.00
- TBPH $77,205,000.00
- Revenue This Year
- SMBK $22.86
- TBPH $79.82
- Revenue Next Year
- SMBK $10.59
- TBPH N/A
- P/E Ratio
- SMBK $14.91
- TBPH $54.21
- Revenue Growth
- SMBK 20.51
- TBPH 24.49
- 52 Week Low
- SMBK $26.31
- TBPH $7.88
- 52 Week High
- SMBK $37.82
- TBPH $14.55
- Technical
- Relative Strength Index (RSI)
- SMBK 54.98
- TBPH 61.75
- Support Level
- SMBK $36.17
- TBPH $13.86
- Resistance Level
- SMBK $37.57
- TBPH $14.42
- Average True Range (ATR)
- SMBK 0.72
- TBPH 0.43
- MACD
- SMBK -0.11
- TBPH -0.07
- Stochastic Oscillator
- SMBK 39.89
- TBPH 53.70
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About TBPH Theravance Biopharma Inc.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).